US FDA Grants Fast Track Designation to Compass Therapeutics’ CTX-009 with Paclitaxel for Previously Treated Metastatic or Locally Advanced Biliary Tract Tumors
Shots:
- Compass received US FDA’s FTD for CTX-009 with paclitaxel to treat metastatic or locally advanced BTC patients that have been previously treated
- Patients in P-II (n=24) study shown 37.5% (n=9/24) ORR, 9.4 mos mPFS, and 12.5 mos mOS; enrolment completion is expected by mid-2024; topline results of COMPANION-002 (P-II/III) study for BTC in US is expected by 2024 end
- CTX-009, a bispecific DLL4/VEGF-A antibody has also shown partial response as monotx in pre-treated cancer patients resistant to other VEGF blockers, whereas current available therapies have low, single digit response rates, and limited effect on patient survival
Ref: Compass Therapeutics| Image: Compass Therapeutics
Related News:- Compass Therapeutics to Present P-II Study Results of CTX-009 + Paclitaxel for Biliary Tract Cancers at ASCO GI 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
